Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin)...
Saved in:
| Published in: | The lancet oncology Vol. 14; no. 13; pp. 1278 - 1286 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Ltd
01.12.2013
Elsevier Limited |
| Subjects: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20–80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699.
Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7–13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7–12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86–1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab).
SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations.
Taiho. |
|---|---|
| AbstractList | Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20–80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699.
Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7–13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7–12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86–1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab).
SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations.
Taiho. Summary Background: Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods: We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7.5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease ( greater than or equal to 20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings: Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11.5 months (95% CI 10.7-13.2) in the group assigned to mFOLFOX6 plus bevacizumab and 11.7 months (10.7-12.9) in the group assigned to SOX plus bevacizumab (HR 1.04, 95% CI 0.86-1.27; less than non-inferiority margin of 1.33, pnon-inferiority=0.014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0.0029) and neutropenia (84 [34%] vs 22 [9%]; p<0.0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0.019) and diarrhoea (23 [9%] vs seven [3%]; p=0.0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation: SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho. Summary Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20–80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2 l -leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7–13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7–12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86–1·27; less than non-inferiority margin of 1·33, pnon-inferiority =0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho. Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m(2) oxaliplatin, 200 mg/m(2)l-leucovorin, 400 mg/m(2) bolus fluorouracil, and 2400 mg/m(2) infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m(2) intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Taiho. Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2 -leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7 times 5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease ( greater than or equal to 20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11 times 5 months (95% CI 10 times 7-13 times 2) in the group assigned to mFOLFOX6 plus bevacizumab and 11 times 7 months (10 times 7-12 times 9) in the group assigned to SOX plus bevacizumab (HR 1 times 04, 95% CI 0 times 86-1 times 27; less than non-inferiority margin of 1 times 33, pnon-inferiority=0 times 014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis six [2%] of 250 given SOX plus bevacizumab; p=0 times 0029) and neutropenia (84 [34%] 22 [9%]; p<0 times 0001). Grade 3 or higher anorexia (13 [5%] three [1%]; p=0 times 019) and diarrhoea (23 [9%] seven [3%]; p=0 times 0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho. Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.BACKGROUNDStudies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m(2) oxaliplatin, 200 mg/m(2)l-leucovorin, 400 mg/m(2) bolus fluorouracil, and 2400 mg/m(2) infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m(2) intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699.METHODSWe undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m(2) oxaliplatin, 200 mg/m(2)l-leucovorin, 400 mg/m(2) bolus fluorouracil, and 2400 mg/m(2) infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m(2) intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699.Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab).FINDINGSBetween Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab).SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations.INTERPRETATIONSOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations.Taiho.FUNDINGTaiho. Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2bolus fluorouracil, and 2400 mg/m2infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (?20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysisvssix [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%]vs22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%]vsthree [1%]; p=0·019) and diarrhoea (23 [9%]vsseven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho. |
| Author | Mishima, Hideyuki Satoh, Taroh Shimada, Yasuhiro Komatsu, Yoshito Takahashi, Keiichi Sugihara, Kenichi Sasaki, Yasutsuna Yoshida, Kazuhiro Watanabe, Masahiko Morita, Satoshi Iwamoto, Shigeyoshi Yamada, Yasuhide Takahari, Daisuke Nakamura, Masato Baba, Hideo Muro, Kei Sakata, Yuh Matsumoto, Hiroshi Yoshida, Motoki Shimada, Ken |
| Author_xml | – sequence: 1 givenname: Yasuhide surname: Yamada fullname: Yamada, Yasuhide email: yayamada@ncc.go.jp organization: National Cancer Center Hospital, Tokyo, Japan – sequence: 2 givenname: Daisuke surname: Takahari fullname: Takahari, Daisuke organization: Aichi Cancer Center Hospital, Nagoya, Japan – sequence: 3 givenname: Hiroshi surname: Matsumoto fullname: Matsumoto, Hiroshi organization: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan – sequence: 4 givenname: Hideo surname: Baba fullname: Baba, Hideo organization: Kumamoto University, Kumamoto, Japan – sequence: 5 givenname: Masato surname: Nakamura fullname: Nakamura, Masato organization: Aizawa Hospital, Matsumoto, Japan – sequence: 6 givenname: Kazuhiro surname: Yoshida fullname: Yoshida, Kazuhiro organization: Gifu University School of Medicine, Gifu, Japan – sequence: 7 givenname: Motoki surname: Yoshida fullname: Yoshida, Motoki organization: Osaka Medical College Hospital, Takatsuki, Japan – sequence: 8 givenname: Shigeyoshi surname: Iwamoto fullname: Iwamoto, Shigeyoshi organization: Kansai Medical University Hirakata Hospital, Hirakata, Japan – sequence: 9 givenname: Ken surname: Shimada fullname: Shimada, Ken organization: Showa University Northern Yokohama Hospital, Yokohama, Japan – sequence: 10 givenname: Yoshito surname: Komatsu fullname: Komatsu, Yoshito organization: Hokkaido University Hospital, Sapporo, Japan – sequence: 11 givenname: Yasutsuna surname: Sasaki fullname: Sasaki, Yasutsuna organization: Showa University, Tokyo, Japan – sequence: 12 givenname: Taroh surname: Satoh fullname: Satoh, Taroh organization: Osaka University, Suita, Japan – sequence: 13 givenname: Keiichi surname: Takahashi fullname: Takahashi, Keiichi organization: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan – sequence: 14 givenname: Hideyuki surname: Mishima fullname: Mishima, Hideyuki organization: Aichi Medical University, Nagakute, Japan – sequence: 15 givenname: Kei surname: Muro fullname: Muro, Kei organization: Aichi Cancer Center Hospital, Nagoya, Japan – sequence: 16 givenname: Masahiko surname: Watanabe fullname: Watanabe, Masahiko organization: Kitasato University School of Medicine, Sagamihara, Japan – sequence: 17 givenname: Yuh surname: Sakata fullname: Sakata, Yuh organization: Misawa City Hospital, Misawa, Japan – sequence: 18 givenname: Satoshi surname: Morita fullname: Morita, Satoshi organization: Kyoto University, Kyoto, Japan – sequence: 19 givenname: Yasuhiro surname: Shimada fullname: Shimada, Yasuhiro organization: National Cancer Center Hospital, Tokyo, Japan – sequence: 20 givenname: Kenichi surname: Sugihara fullname: Sugihara, Kenichi organization: Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24225157$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt9qFDEUxgep2D_6CErAmy3s1CSTzGQVFSm2Cgu92Aq9C5nMGZqaTcZkZnV9T9_HzG6LsCDbq4Rzfuc7JznfcXbgvIMse0nwGcGkfLMgrMI5xYxPSHFaYTbD-c2T7CiFWc6ZEAeb-xY5zI5jvMOYVATzZ9khZZRywquj7M8cBu1XPhg3Ra0dfPBDUNrYKVKuQf6XsqazqjcOdXaIqIZVyv4elqpGKwgxhRY52c-OsZQB10f00_S3aAm9in0KaaS99QF0ryzSymkIaLK4urg-fZtkke_A5VbVkCZKX5Ab10Iwad5-PUUh9fVLE6FB3a2KgArUB6Ps8-xpq2yEF_fnSfbt4vP1-Zd8fnX59fzTPNe8FH0ueCuYUqIWeKY0Y1zVBDDWvG5KThivWEsLACgrqupZ0xS1qDmpSUlLhSltipNsstXtgv8xQOxlGkaDtcqBH6IkFSeUVqLgj0NJkVa0H2UlJaIsCEno6x30Lu3PpTePFJvxYsZFol7dU0O9hEZ2wSxVWMsHGyTg3RbQwccYoJXajLvxrg_KWEmwHE0nN6aTo6MkKeTGdPImVfOd6ocG--o-busgrWhlIMiok0M0NGa0g2y82avwYUdBW-OMVvY7rCH--wsZqcRbkVGDFBuFUeD9_wUeMcBfaiIZIA |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_clcc_2019_01_002 crossref_primary_10_1016_j_ejca_2022_04_009 crossref_primary_10_1016_j_bbapap_2017_01_005 crossref_primary_10_1016_j_heliyon_2024_e36464 crossref_primary_10_1038_s41598_021_84279_6 crossref_primary_10_1007_s00535_021_01798_9 crossref_primary_10_1111_cas_14117 crossref_primary_10_1097_MD_0000000000015999 crossref_primary_10_3892_ol_2018_8628 crossref_primary_10_1007_s13193_016_0543_z crossref_primary_10_1186_s12876_020_01507_5 crossref_primary_10_1007_s10147_020_01646_5 crossref_primary_10_1111_cas_14758 crossref_primary_10_1186_s12885_019_6200_5 crossref_primary_10_3389_fonc_2021_728854 crossref_primary_10_1517_14740338_2016_1146674 crossref_primary_10_1093_jjco_hyx048 crossref_primary_10_1007_s10147_020_01657_2 crossref_primary_10_1016_j_ejca_2022_02_004 crossref_primary_10_1245_s10434_021_10507_y crossref_primary_10_1245_s10434_019_07172_7 crossref_primary_10_3390_jcm9061772 crossref_primary_10_1007_s11605_021_05122_x crossref_primary_10_1038_bjc_2017_128 crossref_primary_10_1016_j_ejca_2018_03_026 crossref_primary_10_1186_s12885_019_5696_z crossref_primary_10_1093_annonc_mdw206 crossref_primary_10_1371_journal_pone_0133133 crossref_primary_10_1016_j_clinthera_2018_05_011 crossref_primary_10_1186_s40064_016_3529_y crossref_primary_10_1016_j_critrevonc_2016_05_015 crossref_primary_10_1016_j_esmogo_2023_08_006 crossref_primary_10_1016_j_jsps_2019_09_004 crossref_primary_10_3892_ol_2017_7261 crossref_primary_10_1007_s00384_025_04962_2 crossref_primary_10_1186_s12885_017_3526_8 crossref_primary_10_1016_j_clbc_2021_01_018 crossref_primary_10_1016_j_radonc_2015_08_002 crossref_primary_10_1517_14656566_2014_937706 crossref_primary_10_1007_s00595_019_01872_z crossref_primary_10_1586_17512433_2016_1133285 crossref_primary_10_1016_S1470_2045_18_30140_2 crossref_primary_10_1007_s00280_015_2825_5 crossref_primary_10_3892_mco_2018_1778 crossref_primary_10_1097_DCR_0000000000001927 crossref_primary_10_2217_fon_2022_1284 crossref_primary_10_1136_bmjopen_2016_011454 crossref_primary_10_1016_j_clcc_2016_09_010 crossref_primary_10_1016_j_critrevonc_2020_102877 crossref_primary_10_1002_ags3_12245 crossref_primary_10_1007_s10147_019_01414_0 crossref_primary_10_9738_INTSURG_D_20_00035_1 crossref_primary_10_3390_ijms18040752 crossref_primary_10_1016_j_lungcan_2015_05_022 crossref_primary_10_1186_s40064_016_3491_8 crossref_primary_10_1016_j_pharmthera_2017_02_028 crossref_primary_10_3389_fphar_2024_1374136 crossref_primary_10_1002_cam4_3095 crossref_primary_10_1007_s10637_018_0697_3 crossref_primary_10_1634_theoncologist_2020_0463 crossref_primary_10_1186_s12885_015_1606_1 crossref_primary_10_1111_cas_14020 crossref_primary_10_1007_s00432_023_04909_6 crossref_primary_10_1007_s10637_021_01162_x crossref_primary_10_1093_jjco_hyac045 crossref_primary_10_1007_s43441_021_00328_2 crossref_primary_10_1016_S1470_2045_13_70533_3 crossref_primary_10_1186_s12885_019_5468_9 crossref_primary_10_1007_s00280_014_2620_8 crossref_primary_10_1016_j_clcc_2016_07_019 crossref_primary_10_1159_000382119 crossref_primary_10_1093_annonc_mdw162 crossref_primary_10_1002_ijc_30127 crossref_primary_10_1007_s12328_021_01525_0 crossref_primary_10_1016_j_clinthera_2025_01_019 crossref_primary_10_1186_s40780_018_0127_x crossref_primary_10_1007_s00280_017_3336_3 crossref_primary_10_1158_1078_0432_CCR_15_3117 crossref_primary_10_1111_cas_12465 crossref_primary_10_1093_jjco_hyy069 crossref_primary_10_1093_oncolo_oyae235 crossref_primary_10_1007_s11418_017_1113_6 crossref_primary_10_1080_00498254_2023_2283736 crossref_primary_10_23922_jarc_2024_085 crossref_primary_10_3748_wjg_v20_i41_15110 crossref_primary_10_1186_s12876_024_03549_5 crossref_primary_10_1007_s00280_019_03901_7 crossref_primary_10_1007_s10147_015_0895_3 crossref_primary_10_1002_ags3_12023 crossref_primary_10_1016_j_clinthera_2022_11_009 crossref_primary_10_1093_annonc_mdx122 crossref_primary_10_1007_s11096_017_0536_1 crossref_primary_10_3390_cancers16142597 crossref_primary_10_1186_1471_2407_14_883 crossref_primary_10_1007_s00595_015_1276_2 crossref_primary_10_1007_s00280_015_2834_4 crossref_primary_10_4993_acrt_26_101 crossref_primary_10_1007_s00280_019_03855_w crossref_primary_10_1093_annonc_mdu232 crossref_primary_10_1007_s10147_018_1308_1 crossref_primary_10_1155_2014_146530 crossref_primary_10_3390_cancers14102470 crossref_primary_10_1007_s40265_014_0302_9 crossref_primary_10_3389_fonc_2019_01367 crossref_primary_10_3892_mco_2016_977 crossref_primary_10_1007_s10120_015_0575_z crossref_primary_10_1007_s10147_025_02804_3 crossref_primary_10_1007_s00280_016_3212_6 crossref_primary_10_1097_MPA_0000000000001879 crossref_primary_10_3892_mco_2018_1791 crossref_primary_10_3892_or_2014_3299 crossref_primary_10_1002_pst_1875 crossref_primary_10_1007_s10120_022_01291_z crossref_primary_10_1007_s10147_020_01788_6 crossref_primary_10_1245_s10434_023_13928_z crossref_primary_10_1002_ags3_12071 crossref_primary_10_1007_s11888_014_0216_7 crossref_primary_10_1038_bjc_2015_10 crossref_primary_10_1016_j_clcc_2017_10_015 crossref_primary_10_3892_ol_2021_12991 crossref_primary_10_1038_srep36944 crossref_primary_10_1177_17588359211009001 crossref_primary_10_1186_s40792_020_01021_6 crossref_primary_10_1016_S1470_2045_15_00411_8 crossref_primary_10_1093_annonc_mdx738 crossref_primary_10_1007_s00280_015_2676_0 crossref_primary_10_1038_nrclinonc_2014_51 crossref_primary_10_1111_jgh_13845 crossref_primary_10_1016_j_clcc_2021_03_001 crossref_primary_10_1007_s00216_014_8350_2 crossref_primary_10_1007_s10120_019_00973_5 crossref_primary_10_1159_000381077 crossref_primary_10_1007_s00280_016_3096_5 crossref_primary_10_1007_s10147_015_0850_3 crossref_primary_10_1016_j_tranon_2019_12_011 crossref_primary_10_1016_j_jgo_2017_08_001 crossref_primary_10_1007_s12029_022_00829_9 crossref_primary_10_1186_s12885_021_08690_y crossref_primary_10_4251_wjgo_v13_i4_295 crossref_primary_10_1159_000369976 crossref_primary_10_2217_fon_15_59 crossref_primary_10_1007_s00270_019_02284_9 crossref_primary_10_1016_j_ejca_2015_03_007 crossref_primary_10_1245_s10434_015_4771_1 crossref_primary_10_1007_s10147_023_02326_w crossref_primary_10_1136_bmjopen_2021_048833 crossref_primary_10_5301_tj_5000211 crossref_primary_10_1002_ags3_12687 crossref_primary_10_1002_ags3_12720 crossref_primary_10_1007_s00280_024_04648_6 crossref_primary_10_1159_000446107 crossref_primary_10_1007_s00432_019_03109_5 crossref_primary_10_1016_j_critrevonc_2016_03_015 crossref_primary_10_1016_j_ejca_2017_02_009 crossref_primary_10_1517_14740338_2016_1105959 crossref_primary_10_1007_s00280_017_3255_3 crossref_primary_10_1007_s00280_018_3714_5 crossref_primary_10_1007_s11418_015_0921_9 crossref_primary_10_1007_s11523_023_00996_0 crossref_primary_10_1007_s00280_016_3040_8 crossref_primary_10_1080_0284186X_2016_1278459 crossref_primary_10_4081_oncol_2020_442 crossref_primary_10_1016_j_nut_2021_111362 crossref_primary_10_1186_s12885_020_07766_5 crossref_primary_10_1080_14656566_2016_1186649 crossref_primary_10_1111_ajco_13404 crossref_primary_10_3109_0284186X_2016_1161825 crossref_primary_10_1007_s00280_021_04232_2 crossref_primary_10_1007_s10147_017_1101_6 crossref_primary_10_1016_j_ejca_2017_05_022 crossref_primary_10_1245_s10434_019_07735_8 crossref_primary_10_1111_cas_14841 crossref_primary_10_1007_s00384_020_03606_x crossref_primary_10_1016_j_esmogo_2024_100090 crossref_primary_10_1093_jjco_hyw086 crossref_primary_10_1186_s12885_021_07823_7 crossref_primary_10_1371_journal_pone_0178221 crossref_primary_10_1136_bcr_2015_213548 crossref_primary_10_1007_s10147_019_01485_z crossref_primary_10_1002_cam4_70940 crossref_primary_10_1186_s40792_017_0338_7 |
| Cites_doi | 10.2307/2529712 10.1158/1078-0432.CCR-07-1225 10.1016/S1470-2045(12)70363-7 10.1200/JCO.2007.14.9898 10.1016/S1470-2045(10)70181-9 10.1093/jnci/92.3.205 10.1200/JCO.2004.05.113 10.1111/j.1349-7006.2010.01793.x 10.1200/JCO.2007.15.2090 10.1200/JCO.1991.9.1.191 10.1200/JCO.2005.03.0106 10.1093/annonc/mdm267 10.1200/JCO.2007.14.9930 10.2307/2983527 10.1093/annonc/mdn721 10.1200/JCO.2007.15.4138 10.1200/JCO.2008.16.7759 10.1200/JCO.2004.09.046 10.1093/annonc/mdl336 10.1038/sj.bjc.6604271 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(13)70490-X |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE Oncogenes and Growth Factors Abstracts MEDLINE - Academic Oncogenes and Growth Factors Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 1286 |
| ExternalDocumentID | 3146031261 24225157 10_1016_S1470_2045_13_70490_X S147020451370490X 1_s2_0_S147020451370490X |
| Genre | Clinical Trial, Phase III Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation | Taiho. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c568t-85f84aa8b809ac445ab1e00c5bd6514574f23eee672ab9dd3b8b51b1626a022d3 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 221 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000327539600040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Wed Oct 01 14:17:35 EDT 2025 Sun Sep 28 00:28:21 EDT 2025 Thu Oct 02 03:54:22 EDT 2025 Tue Oct 07 06:02:58 EDT 2025 Wed Feb 19 01:54:33 EST 2025 Sat Nov 29 07:03:05 EST 2025 Tue Nov 18 21:29:44 EST 2025 Fri Feb 23 02:29:54 EST 2024 Sun Feb 23 10:18:52 EST 2025 Tue Oct 14 19:38:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Language | English |
| License | Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c568t-85f84aa8b809ac445ab1e00c5bd6514574f23eee672ab9dd3b8b51b1626a022d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 24225157 |
| PQID | 1464953958 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1751227835 proquest_miscellaneous_1751213017 proquest_miscellaneous_1462186311 proquest_journals_1464953958 pubmed_primary_24225157 crossref_citationtrail_10_1016_S1470_2045_13_70490_X crossref_primary_10_1016_S1470_2045_13_70490_X elsevier_sciencedirect_doi_10_1016_S1470_2045_13_70490_X elsevier_clinicalkeyesjournals_1_s2_0_S147020451370490X elsevier_clinicalkey_doi_10_1016_S1470_2045_13_70490_X |
| PublicationCentury | 2000 |
| PublicationDate | 2013-12-01 |
| PublicationDateYYYYMMDD | 2013-12-01 |
| PublicationDate_xml | – month: 12 year: 2013 text: 2013-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Cassidy, Clarke, Diaz-Rubio (bib4) 2008; 26 Tournigand, Cervantes, Figer (bib15) 2006; 24 Shuster (bib14) 1991; 9 Andre, Tournigand, Mineur (bib16) 2007; 18 Spiegelhalter, Freedman, Parmar (bib19) 1994; 157 Arkenau, Arnold, Cassidy (bib17) 2008; 26 Therasse, Arbuck, Eisenhauer (bib13) 2000; 92 Tournigand, Andre, Achille (bib2) 2004; 22 Shirasaka (bib5) 2009; 39 Pocock, Simon (bib10) 1975; 31 Yen-Revollo, Goldberg, McLeod (bib18) 2008; 14 Yamada, Tahara, Miya (bib7) 2008; 98 Zang, Lee, Park (bib8) 2009; 20 Muro, Boku, Shimada (bib6) 2010; 11 Saltz, Clarke, Diaz-Rubio (bib3) 2008; 26 Hong, Park, Lim (bib9) 2012; 13 Sorbye, Kohne, Sargent, Glimelius (bib11) 2007; 18 Hochster, Hart, Ramanathan (bib12) 2008; 26 Goldberg, Sargent, Morton (bib1) 2004; 22 Haller, Cassidy, Clarke (bib20) 2008; 26 Chuah, Goh, Lee (bib21) 2011; 102 Spiegelhalter (10.1016/S1470-2045(13)70490-X_bib19) 1994; 157 Shirasaka (10.1016/S1470-2045(13)70490-X_bib5) 2009; 39 Arkenau (10.1016/S1470-2045(13)70490-X_bib17) 2008; 26 Goldberg (10.1016/S1470-2045(13)70490-X_bib1) 2004; 22 Zang (10.1016/S1470-2045(13)70490-X_bib8) 2009; 20 Muro (10.1016/S1470-2045(13)70490-X_bib6) 2010; 11 Tournigand (10.1016/S1470-2045(13)70490-X_bib15) 2006; 24 Hong (10.1016/S1470-2045(13)70490-X_bib9) 2012; 13 Sorbye (10.1016/S1470-2045(13)70490-X_bib11) 2007; 18 Chuah (10.1016/S1470-2045(13)70490-X_bib21) 2011; 102 Shuster (10.1016/S1470-2045(13)70490-X_bib14) 1991; 9 Yamada (10.1016/S1470-2045(13)70490-X_bib7) 2008; 98 Haller (10.1016/S1470-2045(13)70490-X_bib20) 2008; 26 Therasse (10.1016/S1470-2045(13)70490-X_bib13) 2000; 92 Yen-Revollo (10.1016/S1470-2045(13)70490-X_bib18) 2008; 14 Andre (10.1016/S1470-2045(13)70490-X_bib16) 2007; 18 Tournigand (10.1016/S1470-2045(13)70490-X_bib2) 2004; 22 Pocock (10.1016/S1470-2045(13)70490-X_bib10) 1975; 31 Cassidy (10.1016/S1470-2045(13)70490-X_bib4) 2008; 26 Hochster (10.1016/S1470-2045(13)70490-X_bib12) 2008; 26 Saltz (10.1016/S1470-2045(13)70490-X_bib3) 2008; 26 24225156 - Lancet Oncol. 2013 Dec;14(13):1244-5 Lancet Oncol. 2014 Jan;15(1):e4 |
| References_xml | – volume: 98 start-page: 1034 year: 2008 end-page: 1038 ident: bib7 article-title: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer publication-title: Br J Cancer – volume: 157 start-page: 357 year: 1994 end-page: 387 ident: bib19 article-title: Bayesian approaches to randomized trials publication-title: J R Stat Soc – volume: 11 start-page: 853 year: 2010 end-page: 860 ident: bib6 article-title: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) publication-title: Lancet Oncol – volume: 31 start-page: 103 year: 1975 end-page: 115 ident: bib10 article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial publication-title: Biometrics – volume: 18 start-page: 77 year: 2007 end-page: 81 ident: bib16 article-title: Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study publication-title: Ann Oncol – volume: 26 start-page: 2006 year: 2008 end-page: 2012 ident: bib4 article-title: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer publication-title: J Clin Oncol – volume: 26 start-page: 5910 year: 2008 end-page: 5917 ident: bib17 article-title: Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials publication-title: J Clin Oncol – volume: 13 start-page: 1125 year: 2012 end-page: 1132 ident: bib9 article-title: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial publication-title: Lancet Oncol – volume: 102 start-page: 478 year: 2011 end-page: 483 ident: bib21 article-title: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients publication-title: Cancer Sci – volume: 39 start-page: 2 year: 2009 end-page: 15 ident: bib5 article-title: Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas publication-title: J Clin Oncol – volume: 20 start-page: 892 year: 2009 end-page: 896 ident: bib8 article-title: Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer publication-title: Ann Oncol – volume: 26 start-page: 3523 year: 2008 end-page: 3529 ident: bib12 article-title: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study publication-title: J Clin Oncol – volume: 24 start-page: 394 year: 2006 end-page: 400 ident: bib15 article-title: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study publication-title: J Clin Oncol – volume: 26 start-page: 2118 year: 2008 end-page: 2123 ident: bib20 article-title: Potential regional differences for the tolerability profiles of fluoropyrimidines publication-title: J Clin Oncol – volume: 22 start-page: 23 year: 2004 end-page: 30 ident: bib1 article-title: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer publication-title: J Clin Oncol – volume: 92 start-page: 205 year: 2000 end-page: 216 ident: bib13 article-title: New guidelines to evaluate the response to treatment in solid tumors publication-title: J Natl Cancer Inst – volume: 14 start-page: 8 year: 2008 end-page: 13 ident: bib18 article-title: Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? publication-title: Clin Cancer Res – volume: 26 start-page: 2013 year: 2008 end-page: 2019 ident: bib3 article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study publication-title: J Clin Oncol – volume: 18 start-page: 1666 year: 2007 end-page: 1672 ident: bib11 article-title: Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification publication-title: Ann Oncol – volume: 9 start-page: 191 year: 1991 end-page: 192 ident: bib14 article-title: Median follow-up in clinical trials publication-title: J Clin Oncol – volume: 22 start-page: 229 year: 2004 end-page: 237 ident: bib2 article-title: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study publication-title: J Clin Oncol – volume: 31 start-page: 103 year: 1975 ident: 10.1016/S1470-2045(13)70490-X_bib10 article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial publication-title: Biometrics doi: 10.2307/2529712 – volume: 14 start-page: 8 year: 2008 ident: 10.1016/S1470-2045(13)70490-X_bib18 article-title: Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1225 – volume: 13 start-page: 1125 year: 2012 ident: 10.1016/S1470-2045(13)70490-X_bib9 article-title: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70363-7 – volume: 26 start-page: 2006 year: 2008 ident: 10.1016/S1470-2045(13)70490-X_bib4 article-title: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.9898 – volume: 11 start-page: 853 year: 2010 ident: 10.1016/S1470-2045(13)70490-X_bib6 article-title: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70181-9 – volume: 92 start-page: 205 year: 2000 ident: 10.1016/S1470-2045(13)70490-X_bib13 article-title: New guidelines to evaluate the response to treatment in solid tumors publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.3.205 – volume: 22 start-page: 229 year: 2004 ident: 10.1016/S1470-2045(13)70490-X_bib2 article-title: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study publication-title: J Clin Oncol doi: 10.1200/JCO.2004.05.113 – volume: 102 start-page: 478 year: 2011 ident: 10.1016/S1470-2045(13)70490-X_bib21 article-title: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01793.x – volume: 39 start-page: 2 year: 2009 ident: 10.1016/S1470-2045(13)70490-X_bib5 article-title: Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas publication-title: J Clin Oncol – volume: 26 start-page: 2118 year: 2008 ident: 10.1016/S1470-2045(13)70490-X_bib20 article-title: Potential regional differences for the tolerability profiles of fluoropyrimidines publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.2090 – volume: 9 start-page: 191 year: 1991 ident: 10.1016/S1470-2045(13)70490-X_bib14 article-title: Median follow-up in clinical trials publication-title: J Clin Oncol doi: 10.1200/JCO.1991.9.1.191 – volume: 24 start-page: 394 year: 2006 ident: 10.1016/S1470-2045(13)70490-X_bib15 article-title: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.0106 – volume: 18 start-page: 1666 year: 2007 ident: 10.1016/S1470-2045(13)70490-X_bib11 article-title: Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification publication-title: Ann Oncol doi: 10.1093/annonc/mdm267 – volume: 26 start-page: 2013 year: 2008 ident: 10.1016/S1470-2045(13)70490-X_bib3 article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.9930 – volume: 157 start-page: 357 year: 1994 ident: 10.1016/S1470-2045(13)70490-X_bib19 article-title: Bayesian approaches to randomized trials publication-title: J R Stat Soc doi: 10.2307/2983527 – volume: 20 start-page: 892 year: 2009 ident: 10.1016/S1470-2045(13)70490-X_bib8 article-title: Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdn721 – volume: 26 start-page: 3523 year: 2008 ident: 10.1016/S1470-2045(13)70490-X_bib12 article-title: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.4138 – volume: 26 start-page: 5910 year: 2008 ident: 10.1016/S1470-2045(13)70490-X_bib17 article-title: Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.7759 – volume: 22 start-page: 23 year: 2004 ident: 10.1016/S1470-2045(13)70490-X_bib1 article-title: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2004.09.046 – volume: 18 start-page: 77 year: 2007 ident: 10.1016/S1470-2045(13)70490-X_bib16 article-title: Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study publication-title: Ann Oncol doi: 10.1093/annonc/mdl336 – volume: 98 start-page: 1034 year: 2008 ident: 10.1016/S1470-2045(13)70490-X_bib7 article-title: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604271 – reference: 24225156 - Lancet Oncol. 2013 Dec;14(13):1244-5 – reference: - Lancet Oncol. 2014 Jan;15(1):e4 |
| SSID | ssj0017105 |
| Score | 2.5511205 |
| Snippet | Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer.... Summary Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic... Summary Background: Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic... Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1278 |
| SubjectTerms | Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Cancer therapies Chemotherapy Chemotherapy, Adjuvant Clinical trials Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Creatinine Diarrhea Disease-Free Survival Drug Administration Schedule Drug Combinations Drug dosages Ethics Female Fluorouracil - administration & dosage Hematology, Oncology and Palliative Medicine Humans Infusions, Intravenous Japan Kaplan-Meier Estimate Leucovorin - administration & dosage Male Metastasis Middle Aged Neoplasm Staging Neutrophils Organoplatinum Compounds - administration & dosage Oxonic Acid - administration & dosage Tegafur - administration & dosage Toxicity Treatment Outcome |
| Title | Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S147020451370490X https://www.clinicalkey.es/playcontent/1-s2.0-S147020451370490X https://dx.doi.org/10.1016/S1470-2045(13)70490-X https://www.ncbi.nlm.nih.gov/pubmed/24225157 https://www.proquest.com/docview/1464953958 https://www.proquest.com/docview/1462186311 https://www.proquest.com/docview/1751213017 https://www.proquest.com/docview/1751227835 |
| Volume | 14 |
| WOSCitedRecordID | wos000327539600040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (Proquest) customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwELZgQ2gv_IYVxmQkHjapZnFi1w4vCKZVPIwyrWPqm-U4jqjUJaVpKsT_yf_DXZJmL2xF4sUPji85JZ_vvtjnO0LeCqm5A8fDhBCSCe0dS2wWMx8J5b0Hn1lHW1yeqtFITybxWbvgVrZhlWubWBvqtHC4Rn4EMxpDIWOpP8x_MKwahburbQmNu2SbIzcGPKvzy24XQTUhjFyogGHa9esTPEfjrvOAR4cK97_Y5CbfdBP3rH3Q8OH_av-IPGjZJ_3YwOUxuePzJ-T-l3Z__Sn5feorV6wwKK9Ps1lVLEDCuumsT22e0uInsPY5Rs_ldD6rSpr4FVz9VV3ZhGJ8B3SNGd88FvuahK4lxZVgeuWXFs82TR3FNNpohkFPh5Bc0IPx1-HF4Xu4LcViXwyA60GjvMgZxpItpgVW4OtTcLtpAbj1KZ1_B-9MI1oXJXlGvg1PLo4_s7bwA3NyoJdMy0wLa3Wig9g6AJFNuA8CJ5N0AARPKpGFESJJhTaJ0zRKdCJ5wuHnzAInSaPnZAt08LuEZrHQIrF6oL0WkmfW61SFgUszHvpBFPSIWH9y49qs6FicY2a68DdEikGkGB6ZGilm0iPvOrF5kxZkk8BgjSezPvMKVtqA49okqP4m6MvW1pSGmzI0QSONwjyqRUFSd5ItnWpo0r88dG8NY3P9nA7DPfKmuwxfFbeYbO6Lqh6DRc4izm8ZoyTmEYTpuWEMFoGRPfKimXLdewZSCaRcqpe3K_mK7IRYuqQOPdojW8tF5V-Te261nJaL_dpQYDtRdauh1cd8n2x_Ohmdnf8B9axx4w |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90thgJFA2qSaxYlTO0gIIaDatK4gtUN9M47jiEpdU5q2XH4U_4b_wzm57YWtvOyBV8cnOXLO1f58DiHPRKi4BcfDhBAhE8pZFps0Yi4Q0jkHPrNAW3zqyX5fjUbRxw3yq74Lg7DK2iYWhjrJLO6R74JGIxQyCtXr2VeGXaPwdLVuoVGKxYH78Q1StvzV_jv4v899v_t--HaPVV0FmA07asFUmCphjIqVFxkLHJqYO8-zYZx0IHoIpUj9ANmUvomjJAliFYc85hD5G3B4SQDvvUAugh2XmOzJUZPgcVlCJrmQHsMy7yc3hnYHzeA2D3Yknrex0Wm-8LRYt_B53ev_22rdINeq6Jq-KdXhJtlw01vk8mGFH7hNfvfc0mYrBB22aTpZZnOgMHY8aVMzTWj2HbKSGaIDp3Q2WeY0dit4-nN5bGKK-BUYGjC-fi6OlQVrc4o73fTYLQze3RpbimXC0c0AnxZVbk63Bx-6w52X8FqKzcwYKKYDjqbZlCFWbj7OsMNgm0JYkWSgly6hsy8QfdCAFk1X7pCjc1nUu2QTeHD3CU0joURsVEc5JUKeGqcS6Xs2SbnvOoHXIqIWMW2rqu_YfGSiG3gfSqZGydQ80IVk6lGLvGjIZmXZk3UEnVp-dX2nF7yQBse8jlD-jdDllS3NNde5r72SGol5UJACpWooq3CxDAP_5aNbtdrok-80OtMiT5vH8FfxCM1MXbYs5mATt4DzM-bIEOskgjlYMweb3IQtcq9U8WadIWiGpCOUD85m8gm5sjc87Onefv_gIbnqY5uWAma1RTYX86V7RC7Z1WKczx8XRoqSz-et538AiorKgQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMv3C-FAUYCaZNqGidO4yAhhDYqppUyqQP1zTiOIyp1SWmacvlp_A_-D-fkthe28rIHXh2f5Mg5V_vzOYQ8E77kBhwPE0L4TEhrWKSTkFlPBNZa8Jkl2uLTMBiN5GQSHm2QX81dGIRVNjaxNNRxZnCPvAcajVDI0Je9pIZFHO0PXs-_MuwghSetTTuNSkQO7Y9vkL7lrw724V8_d93B2-O9d6zuMMCM35dLJv1ECq1lJJ1QG-BWR9w6jvGjuA-RhB-IxPWQ5cDVURjHXiQjn0ccsgANzi_24L2XyOXA63uY-Mm9Fl7Cgwo-yUXgMCz5fnp7qDduB3e4txvg2RubnOUXz4p7S_83uP4_r9wNcq2OuumbSk1ukg2b3iJb72tcwW3ye2gLk60QjNilyazIFkChzXTWpTqNafYdspU5ogZTOp8VOY3sCp7-LE50RBHXAkNjxtfPxbGqkG1OcQecntilxjtdU0OxfDi6H-DToCou6M74w-B49yW8lmKTMwYKa4GjNEsZYugW0ww7D3YphBtxBvpqYzr_AlEJ9WjZjOUO-Xghi3qXbAIP9j6hSSikiLTsSyuFzxNtZRy4jokT7tq-53SIaMRNmboaPDYlmakW9odSqlBKFfdUKaVq0iEvWrJ5VQ5lHUG_kWXV3PUF76TAYa8jDP5GaPPaxuaKq9xVTkWNxNwrSYFStpR1GFmFh__y0e1GhdTpd1r96ZCn7WP4q3i0plObFeUcbO7mcX7OnMDH-olgGtbMweY3fofcq9S9XWcIpiEZ8YMH5zP5hGyBeqvhwejwIbnqYveWEn21TTaXi8I-IlfMajnNF49Le0XJ54tW8z97HtMI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Leucovorin%2C+fluorouracil%2C+and+oxaliplatin+plus+bevacizumab+versus+S-1+and+oxaliplatin+plus+bevacizumab+in+patients+with+metastatic+colorectal+cancer+%28SOFT%29%3A+an+open-label%2C+non-inferiority%2C+randomised+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Yamada%2C+Yasuhide&rft.au=Takahari%2C+Daisuke&rft.au=Matsumoto%2C+Hiroshi&rft.au=Baba%2C+Hideo&rft.date=2013-12-01&rft.issn=1470-2045&rft.volume=14&rft.issue=13&rft.spage=1278&rft.epage=1286&rft_id=info:doi/10.1016%2FS1470-2045%2813%2970490-X&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204513X7158X%2Fcov150h.gif |